Brief: Santhera And Cold Spring Harbor Laboratory To Investigate Lonodelestat In COVID-19-Related ARDS
April 27 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
SANN.S :
* SANTHERA AND COLD SPRING HARBOR LABORATORY TO INVESTIGATE
LONODELESTAT (POL6014) IN COVID-19-RELATED ACUTE RESPIRATORY
DISTRESS SYNDROME
Source text for Eikon: ID:nGNEbC4yZf
Further company coverage: SANN.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million